Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This placebo controlled study is intended to generate safety and efficacy data in order to
provide a treatment option for COVID-19 in patients with a high risk of disease progression
based on age or co-morbid medical conditions.